Regeneron Mission Statement & Purpose of Investigator-Initiated Study Program:
The mission of the Regeneron Investigator-Initiated Study (IIS) Program is to enhance the understanding of disease entities and their treatment through the support of investigator-initiated original research that will advance the delivery of quality healthcare.
The IIS Program will consider independent, unsolicited IIS research proposals submitted electronically, by external investigators interested in studying Regeneron products and drug candidates in disease states of interest, as well as preclinical, sample analysis and other non-interventional studies focused on Regeneron's areas of interest. Please note drug candidates include compounds developed by Regeneron in collaboration with Sanofi. Specifically, these are Alirocumab (anti-PCSK9), Dupilumab (anti-IL-4) and Sarilumab (anti-IL-6). Support, if any, will be granted on the basis of scientific merit. The IIS budget must be reasonable and appropriate for the study. Scientific expertise will also be considered.
All proposals will be reviewed by the IIS Program Committee which is comprised of a cross-functional team.
If approved, the IIS Program typically provides a research grant in the manner of funding and/or drug product. Regeneron provides no guarantees that it will provide support for submitted proposals. The terms under which Regeneron will provide support will be set forth in a written agreement.
IIS Areas of Interest:
- Ophthalmic neovascular diseases
- Inflammatory diseases
- Auto-immune conditions
At a minimum, your submission must contain the following documents before it will be submitted to the Regeneron IIS Committee for review:
- IIS Concept Proposal Submission Form (completed)
- Requested Support (Drug, Funding, or both)
- Drug Supply Request
- Preliminary Budget (including Direct, Indirect, per Patient Costs, and Fees)
- Investigator(s) CV(s)
- Please see our Terms and Conditions for further information.
The IIS Program Committee routinely meets to review IIS proposals. Incomplete submissions may cause a delay in the Committee’s review and response.
*All submitted requests and documents are considered Non-Confidential
If you would like to discuss your concept or submission requirements/forms prior to submitting your proposal, please send an email to IIS.Grants@regeneron.com and your local Regeneron Science Manager (RSM) will contact you.